Le Lézard
Classified in: Health
Subjects: PDT, FDA

Peleton Surgical Receives First-Ever FDA Clearance to Market Innovative Single-Use Surgical Power Driver


Peleton's surgical power innovation program enhances financial control, improves surgical flexibility, and reduces patient risk.

SCOTTSDALE, Ariz., April 9, 2024 /PRNewswire-PRWeb/ -- Peleton Surgical today announced that it has received FDA clearance (K240071) to market its innovative single-use surgical power driver. The costs and patient risk associated with re-usable surgical drivers represent a challenge for healthcare facilities, and Peleton Surgical's solution will improve patient safety, enable better economics, and ease workflows for surgeons and staff. The elegant design of the Peleton single-use power driver offers great precision and ergonomics, and the power driver is launched with a patented solution for charging the driver through the sterile barrier of the packaging. The drivers and accessories are delivered to the surgery centers and hospitals fully charged, sterile, and ready to use in the operating room.

"We listened to surgeons, nurses, and administrators when designing our breakthrough single-use surgical power driver. The integrated battery pack solves a lot of practical challenges for OR staff and actually helps reduce cost per use."

"We listened to surgeons, nurses, and administrators when designing our breakthrough single-use surgical power driver and attachments. The integrated battery pack solves a lot of practical challenges for OR staff and actually helps reduce cost per use," says Andy Bala, CEO and Director at Peleton Surgical. "At the same time, we were able to address nurse, surgeon, and SPD concerns about patient safety related to the reprocessing of reusable drivers and their attachments."

The FDA clearance is the first-ever for a single-use surgical power driver, and FDA created a new product category to pursue the evaluation and clearance for the device. Peleton Surgical wanted FDA to undertake a thorough review of functional and safety data associated with the use of a surgical power driver, to create standards in an area where improper cleaning and frequent battery charges can result in patient risk and operational inefficiencies. As a result, Peleton went through very extensive testing prior to FDA clearance being granted. Testing involved the surgical driver, its attachments, and its accessories, all from leading surgical power driver manufacturers.

About Peleton Surgical
Peleton Surgical is a surgical power company founded in 2019. The company is focused on enabling surgeons and healthcare facilities to improve efficiencies and reduce costs while ensuring patient safety. Peleton's innovative surgical power solutions improve financial control, versatility, and patient safety. It's power simplified. The company recently received the first-ever FDA clearance for a single-use power driver.

Media Contact

Lori Luechtefeld, WIT Strategy for Peleton Surgical, 310-210-4757, [email protected], https://peletonsurgical.com 

SOURCE Peleton Surgical


These press releases may also interest you

at 08:00
Genetic Technologies Limited , a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the execution of a strategic joint sales & marketing agreement with US based Wellworks for You Inc. (Wellworks). As...

at 07:59
To commemorate this significant declaration, CooperRiis Healing Community will host a special event on May 20th, at 9:30 am. The event...

at 07:50
Calyx, a leading technology-enabled provider of Medical Imaging services and IRT/RTSM (Interactive Response Technology/Randomized Trial Supply Management) today announced its role in supporting the imaging-based endpoint for the pivotal trial that...

at 07:45
Endo, Inc. announced today that its Endo Injectable Solutions business unit launched its enhanced ready-to-use product line and platform, TruDelivery®, underscoring the company's commitment to building its ready-to-administer and ready-to-use...

at 07:35
Gossamer Bio, Inc. ("Gossamer") , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and Chiesi Farmaceutici S.p.A ("Chiesi Group"), an...

at 07:30
Quipt Home Medical Corp. (the "Company") , a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal second quarter 2024 financial results on Wednesday, May 15, 2024. Gregory Crawford, Chief...



News published on and distributed by: